Search

Your search keyword '"Goy, Andre"' showing total 1,498 results
Start Over Author "Goy, Andre"
1,498 results on '"Goy, Andre"'

151. Long-Term Survival and Gradual Recovery of B Cells in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel)

Author

Jacobson, Caron A., primary, Locke, Frederick L., additional, Ghobadi, Armin, additional, Miklos, David B., additional, Lekakis, Lazaros J., additional, Oluwole, Olalekan O., additional, Lin, Yi, additional, Braunschweig, Ira, additional, Hill, Brian T., additional, Timmerman, John M., additional, Deol, Abhinav, additional, Reagan, Patrick M., additional, Stiff, Patrick, additional, Flinn, Ian W., additional, Farooq, Umar, additional, Goy, Andre H., additional, McSweeney, Peter A., additional, Munoz, Javier, additional, Siddiqi, Tanya, additional, Rossi, John M., additional, Bot, Adrian, additional, Zheng, Lianqing, additional, Vezan, Remus, additional, Bashir, Zahid, additional, Kim, Jenny J., additional, Chu, Rong, additional, and Neelapu, Sattva S., additional

Published
2021
Full Text
View/download PDF

152. One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients (Pts) with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

Author

Wang, Michael L., primary, Munoz, Javier, additional, Goy, Andre H., additional, Locke, Frederick L., additional, Jacobson, Caron A., additional, Hill, Brian T., additional, Timmerman, John M., additional, Holmes, Houston, additional, Jaglowski, Samantha, additional, Flinn, Ian W., additional, McSweeney, Peter A., additional, Miklos, David B., additional, Pagel, John M., additional, Kersten, Marie José, additional, Milpied, Noel, additional, Fung, Henry, additional, Topp, Max S., additional, Houot, Roch, additional, Beitinjaneh, Amer, additional, Peng, Weimin, additional, Zheng, Lianqing, additional, Rossi, John M., additional, Murugappan, Swaminathan, additional, Kloos, Ioana, additional, and Reagan, Patrick M., additional

Published
2021
Full Text
View/download PDF

153. Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients (Pts) with Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

Author

Wang, Michael L., primary, Rossi, John M., additional, Munoz, Javier, additional, Goy, Andre H., additional, Locke, Frederick L., additional, Reagan, Patrick M., additional, Jacobson, Caron A., additional, Hill, Brian T., additional, Holmes, Houston, additional, Jaglowski, Samantha, additional, Peng, Weimin, additional, Zheng, Lianqing, additional, Fang, Xiang, additional, Xue, Allen, additional, Kloos, Ioana, additional, and Bot, Adrian, additional

Published
2021
Full Text
View/download PDF

155. The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

Author

Ujjani,Chaitra, Mato,Anthony, Hill,Brian T, Allan,John N, Lansigan,Frederick, Jacobs,Ryan, Skarbnik,Alan, Tuncer,Hande, Pagel,John, Brander,Danielle, Cheson,Bruce, Barr,Paul, Roeker,Lindsey E, Pu,Jeffrey, Shah,Nirav N, Goy,Andre, Schuster,Stephen J, Lamanna,Nicole, Sehgal,Alison, Tam,Constantine S, and Shadman,Mazyar

Subjects
ibrutinib, elderly, Targets and Therapy [Blood and Lymphatic Cancer], CLL, Original Research
Abstract

Chaitra Ujjani, 1 Anthony Mato, 2 Brian T Hill, 3 John N Allan, 4 Frederick Lansigan, 5 Ryan Jacobs, 6 Alan Skarbnik, 7 Hande Tuncer, 8 John Pagel, 9 Danielle Brander, 10 Bruce Cheson, 11 Paul Barr, 12 Lindsey E Roeker, 2 Jeffrey Pu, 13 Nirav N Shah, 14 Andre Goy, 15Stephen J Schuster, 16 Nicole Lamanna, 17 Alison Sehgal, 18 Constantine S Tam, 19 Mazyar Shadman 1 1Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 2Division of Hematological Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; 4Division of Hematology and Medical Oncology, New York Presbyterian & Weill Cornell, New York, NY, USA; 5Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA; 6Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC, USA; 7Novant Health Cancer Institute, Charlotte, NC 28204, USA; 8Lowell General Hospital, Tufts Medical Center, Boston, MA, USA; 9Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA; 10Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA; 11Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA; 12Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; 13Division of Hematology/Oncology, SUNY Upstate Medical University, Syracuse, NY, USA; 14Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; 15John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; 16Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; 17Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA; 18University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 19Peter McCallum Cancer Centre, University of Melbourne, East Melbourne, VI, AustraliaCorrespondence: Chaitra UjjaniSeattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, 825 Eastlake Ave E, Mail Stop CE3-300, Seattle, WA, USATel +1 206-606-1955Fax +1 206-606-1130Email ujjani@uw.eduIntroduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a patient population aged at least 65 years compared to ECOG 1912, which included patients up to 70 years of age.Methods: Therefore, we conducted a retrospective analysis to investigate whether ibrutinib was associated with a greater mortality in older patients outside of a clinical trial setting. This multicenter analysis was performed by investigators at 20 academic and community practices.Results: Amongst the 391 patients included, there was no correlation between age and response rate, PFS, or OS. However, there was a trend to higher rate of deaths in patients > 65-years-old (8.7% vs 3.8%, p=0.097), with an increased number of early deaths (13 vs 4, p=0.3).Conclusion: These data suggest greater intolerance, and possibly mortality, with ibrutinib in an older population. Patients should be educated regarding the potential complications related to ibrutinib and symptoms of concern to report.Keywords: CLL, ibrutinib, elderly

Published
2020

156. Additional file 14 of Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPs

Author

Do, Catherine, Dumont, Emmanuel L. P., Salas, Martha, Castano, Angelica, Huthayfa Mujahed, Maldonado, Leonel, Arunjot Singh, DaSilva-Arnold, Sonia C., Bhagat, Govind, Soren Lehman, Christiano, Angela M., Madhavan, Subha, Nagy, Peter L., Green, Peter H. R., Feinman, Rena, Trimble, Cornelia, Illsley, Nicholas P., Marder, Karen, Honig, Lawrence, Monk, Catherine, Goy, Andre, Kar Chow, Goldlust, Samuel, Kaptain, George, Siegel, David, and Tycko, Benjamin

Abstract

Additional file 14. Review history.

Published
2020
Full Text
View/download PDF

157. Additional file 2 of Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPs

Author

Do, Catherine, Dumont, Emmanuel L. P., Salas, Martha, Castano, Angelica, Huthayfa Mujahed, Maldonado, Leonel, Arunjot Singh, DaSilva-Arnold, Sonia C., Bhagat, Govind, Soren Lehman, Christiano, Angela M., Madhavan, Subha, Nagy, Peter L., Green, Peter H. R., Feinman, Rena, Trimble, Cornelia, Illsley, Nicholas P., Marder, Karen, Honig, Lawrence, Monk, Catherine, Goy, Andre, Kar Chow, Goldlust, Samuel, Kaptain, George, Siegel, David, and Tycko, Benjamin

Subjects
respiratory system, musculoskeletal system, respiratory tract diseases
Abstract

Additional file 2: Figure S1. Flow charts and diagram of computational and analytical approaches in this study. Figure S2. Summary of sample types and numbers and yield of informative SNPs. Figure S3. PCA of the combined WGBS and SureSelect methyl-seq data and series-wide overlap between ASM loci detected by the two methods. Figure S4. Distribution of ASM shows a high proportion of rare or private ASM in both cancer and normal samples and a significant increase in per-sample ASM in the cancers. Figure S5. Comparison of results from individual DNA samples analyzed by two WGBS library construction kits at two sequencing facilities, or by SureSelect and WGBS. Figure S6. Example of a chromosome region illustrating consistency between SureSelect methyl-seq, WGBS, and targeted bisulfite sequencing. Figure S7. Validations of ASM DMRs in disease-associated chromosomal regions: rs10411630 and multiple sclerosis. Figure S8. Validation of ASM DMRs in disease-associated chromosomal regions: rs2427290 and colorectal cancer. Figure S9. Validation of ASM DMRs in disease-associated chromosomal regions: rs2283639 and non-small cell lung carcinoma. Figure S10. Validations of ASM DMRs spanning a range of ASM ranks. Figure S11. Kernel density plots of methylation levels showing global hypomethylation and decrease in the percentage of highly methylated CpGs in cancers. Figure S12. Replication of the findings using WGBS from a single facility. Figure S13. Allele-specific losses of methylation leading to ASM in cancers. Figure S14. Kernel density plots of methylation level distributions showing statistically enriched instances of allele-specific gains of methylation in cancers. Figure S15. Shared ASM loci in cancer and non-cancer have similar ASM magnitude. Figure S16. Correlations between allelic TF binding affinity scores and ASM magnitude in the 4 classes of ASM loci. Figure S17. Examples of ASM DMRs in chromatin deserts. Figure S18. Models for inter-individual variability and allele-switching at ASM loci. Figure S19. The percentage of ASM loci that show switching behavior in cancers is smaller when considering only loci for which ASM is also detected in non-cancer samples. Figure S20. Examples of haplotype blocks defined by stringent and lenient parameters. Figure S21. Utility of D’ and R-square parameters for assessing candidate disease-associated rSNPs. Figure S22. Additional examples of mechanistically informative disease associated ASM index SNPs: autoimmune and neuropsychiatric. Figure S23. Additional examples of mechanistically informative disease associated ASM index SNPs: breast cancer and lymphoma. Figure S24. ASM loci displayed as annotated genome browser tracks.

Published
2020
Full Text
View/download PDF

159. Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel

Author

Spiegel, Jay Y, primary, Dahiya, Saurabh, additional, Jain, Michael D., additional, Tamaresis, John S, additional, Nastoupil, Loretta, additional, Jacobs, Miriam T, additional, Ghobadi, Armin, additional, Lin, Yi, additional, Lunning, Matthew, additional, Lekakis, Lazaros John, additional, Reagan, Patrick, additional, Oluwole, Olalekan O, additional, McGuirk, Joseph P, additional, Deol, Abhinav, additional, Goy, Andre, additional, Vu, Khoan, additional, Andreadis, Charalambos, additional, Munoz, Javier, additional, Bennani, N. Nora, additional, Vose, Julie, additional, Dorritie, Kathleen A, additional, Neelapu, Sattva S., additional, Locke, Frederick L., additional, Rapoport, Aaron P., additional, Hill, Brian, additional, and Miklos, David B, additional

Published
2020
Full Text
View/download PDF

160. Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study

Author

Wang, Michael, primary, Rule, Simon, additional, Zinzani, Pier Luigi, additional, Goy, Andre H., additional, Casasnovas, Rene-Olivier, additional, Smith, Stephen D., additional, Damaj, Gandhi Laurent, additional, Doorduijn, Jeanette K., additional, Lamy, Thierry, additional, Morschhauser, Franck, additional, Panizo, Carlos, additional, Shah, Bijal, additional, Davies, Andrew, additional, Eek, Richard, additional, Dupuis, Jehan, additional, Jacobsen, Eric, additional, Kater, Arnon P., additional, Le Gouill, Steven, additional, Oberic, Lucie, additional, Robak, Tadeusz, additional, Jain, Preetesh, additional, Brock, Graham, additional, Patel, Priti, additional, Tao, Lin, additional, and Dlugosz-Danecka, Monika, additional

Published
2020
Full Text
View/download PDF

161. Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

Author

Wang, Michael, primary, Rossi, John M., additional, Munoz, Javier, additional, Goy, Andre H., additional, Locke, Frederick L., additional, Reagan, Patrick M., additional, Jacobson, Caron A., additional, Hill, Brian T., additional, Holmes, Houston, additional, Jaglowski, Samantha, additional, Peng, Weimin, additional, Zheng, Lianqing, additional, Fang, Xiang, additional, Xue, Allen, additional, Kloos, Ioana, additional, and Bot, Adrian, additional

Published
2020
Full Text
View/download PDF

163. Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Author

Matasar, Matthew J, primary, Cheah, Chan Yoon, additional, Yoon, Dok Hyun, additional, Assouline, Sarit E, additional, Bartlett, Nancy L., additional, Ku, Matthew, additional, Giri, Pratyush, additional, Johnston, Anna, additional, Flinn, Ian W., additional, Goy, Andre H., additional, Tzachanis, Dimitrios, additional, O'Hear, Carol, additional, Yin, Shen, additional, To, Iris, additional, Sarouei, Kati, additional, Li, Chi-Chung, additional, Bender, Brendan C., additional, Penuel, Elicia M., additional, Huang, Huang, additional, and Budde, L. Elizabeth, additional

Published
2020
Full Text
View/download PDF

164. Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study

Author

Schuster, Michael W., primary, Canales, Miguel A, additional, Westin, Jason, additional, Zijlstra, Josée M, additional, Follows, George A, additional, Karmali, Reem, additional, Kalakonda, Nagesh, additional, Goy, Andre H., additional, Casasnovas, Rene-Olivier, additional, Vermaat, Joost, additional, Van Den Neste, Eric, additional, Choquet, Sylvain, additional, Thieblemont, Catherine, additional, Cavallo, Federica, additional, De La Cruz, Maria de Fatima, additional, Hill, Brian T., additional, Tilly, Herve, additional, Kassam, Shireen, additional, Bouabdallah, Reda, additional, Jaeger, Ulrich, additional, Gurion, Ronit, additional, Caimi, Paolo, additional, Martin, Peter, additional, Davies, Andrew, additional, Smith, Sonali M., additional, Collins, Graham P., additional, Offner, Fritz C., additional, Salles, Gilles, additional, Ma, Xiwen, additional, Corona, Kelly, additional, Saint-Martin, Jean-Richard, additional, Joshi, Anita A., additional, Chamoun, Kamal, additional, Wang, Hongwei, additional, Shah, Jatin J., additional, Shacham, Sharon, additional, Kauffman, Michael G, additional, and Maerevoet, Marie, additional

Published
2020
Full Text
View/download PDF

165. Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study

Author

Schuster, Michael W., primary, Canales, Miguel A, additional, Westin, Jason, additional, Zijlstra, Josée M, additional, Follows, George A, additional, Karmali, Reem, additional, Kalakonda, Nagesh, additional, Goy, Andre H., additional, Casasnovas, Rene-Olivier, additional, Vermaat, Joost, additional, Van Den Neste, Eric, additional, Choquet, Sylvain, additional, Thieblemont, Catherine, additional, Cavallo, Federica, additional, De La Cruz, Maria de Fatima, additional, Hill, Brian T., additional, Tilly, Herve, additional, Kassam, Shireen, additional, Bouabdallah, Reda, additional, Jaeger, Ulrich, additional, Gurion, Ronit, additional, Caimi, Paolo, additional, Martin, Peter, additional, Davies, Andrew, additional, Smith, Sonali M., additional, Collins, Graham P., additional, Offner, Fritz C., additional, Salles, Gilles, additional, Ma, Xiwen, additional, Corona, Kelly, additional, Saint-Martin, Jean-Richard, additional, Joshi, Anita A., additional, Chamoun, Kamal, additional, Wang, Hongwei, additional, Shah, Jatin J., additional, Shacham, Sharon, additional, Kauffman, Michael G, additional, and Maerevoet, Marie, additional

Published
2020
Full Text
View/download PDF

167. 507 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of Zuma-1 Cohort 6

Author

Oluwole, Olalekan O., Forcade, Edouard, Muñoz, Javier, de Guibert, Sophie, Vose, Julie M., Bartlett, Nancy L., Lin, Yi, Deol, Abhinav, McSweeney, Peter A., Goy, Andre H., Kersten, Marie José, Jacobson, Caron A., Farooq, Umar, Minnema, Monique C., Thieblemont, Catherine, Timmerman, John M., Stiff, Patrick, Avivi, Irit, Tzachanis, Dimitrios, Zheng, Yan, Vardhanabhuti, Saran, Nater, Jenny, Shen, Rhine R., Miao, Harry, Kim, Jenny J., and van Meerten, Tom

Published
2023
Full Text
View/download PDF

168. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas

Author

Hagemeister, Fredrick, Rodriguez, Maria Alma, Deitcher, Steven R., Younes, Anas, Fayad, Luis, Goy, Andre, Dang, Nam H., Forman, Arthur, McLaughlin, Peter, Medeiros, Leonard Jeffrey, Pro, Barbara, Romaguera, Jorge, Samaniego, Felipe, Silverman, Jeffrey A., Sarris, Andreas, and Cabanillas, Fernando

Published
2013
Full Text
View/download PDF

169. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Author

Wang, Michael L., Rule, Simon, Martin, Peter, Goy, Andre, Auer, Rebecca, Kahl, Brad S., Jurczak, Wojciech, Advani, Ranjana H., Romaguera, Jorge E., Williams, Michael E., Barrientos, Jacqueline C., Chmielowska, Ewa, Radford, John, Stilgenbauer, Stephan, Dreyling, Martin, Jedrzejczak, Wieslaw Wiktor, Johnson, Peter, Spurgeon, Stephen E., Li, Lei, Zhang, Liang, Newberry, Kate, Ou, Zhishuo, Cheng, Nancy, Fang, Bingliang, McGreivy, Jesse, Clow, Fong, Buggy, Joseph J., Chang, Betty Y., Beaupre, Darrin M., Kunkel, Lori A., and Blum, Kristie A.

Published
2013
Full Text
View/download PDF

174. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study

Author

Ip, Andrew, primary, Ahn, Jaeil, additional, Zhou, Yizhao, additional, Goy, Andre H., additional, Hansen, Eric, additional, Pecora, Andrew L, additional, Sinclaire, Brittany A, additional, Bednarz, Urszula, additional, Marafelias, Michael, additional, Mathura, Shivam, additional, Sawczuk, Ihor S, additional, Underwood, Joseph P., additional, Walker, David M., additional, Prasad, Rajiv, additional, Sweeney, Robert L., additional, Ponce, Marie G., additional, Capra, Samuel La, additional, Cunningham, Frank J., additional, Calise, Arthur G., additional, Pulver, Bradley L., additional, Ruocco, Dominic, additional, Mojares, Greggory E., additional, Eagan, Michael P., additional, Ziontz, Kristy L., additional, Mastrokyriakos, Paul, additional, and Goldberg, Stuart L, additional

Published
2020
Full Text
View/download PDF

175. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study

Author

Ip, Andrew, primary, Berry, Donald A., additional, Hansen, Eric, additional, Goy, Andre H., additional, Pecora, Andrew L., additional, Sinclaire, Brittany A., additional, Bednarz, Urszula, additional, Marafelias, Michael, additional, Berry, Scott M., additional, Berry, Nicholas S., additional, Mathura, Shivam, additional, Sawczuk, Ihor S., additional, Biran, Noa, additional, Go, Ronaldo C., additional, Sperber, Steven, additional, Piwoz, Julia A., additional, Balani, Bindu, additional, Cicogna, Cristina, additional, Sebti, Rani, additional, Zuckerman, Jerry, additional, Rose, Keith M., additional, Tank, Lisa, additional, Jacobs, Laurie G., additional, Korcak, Jason, additional, Timmapuri, Sarah L., additional, Underwood, Joseph P., additional, Sugalski, Gregory, additional, Barsky, Carol, additional, Varga, Daniel W., additional, Asif, Arif, additional, Landolfi, Joseph C., additional, and Goldberg, Stuart L., additional

Published
2020
Full Text
View/download PDF

176. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Author

Fraser, Graeme A.M., primary, Chanan-Khan, Asher, additional, Demirkan, Fatih, additional, Santucci Silva, Rodrigo, additional, Grosicki, Sebastian, additional, Janssens, Ann, additional, Mayer, Jiri, additional, Bartlett, Nancy L., additional, Dilhuydy, Marie-Sarah, additional, Loscertales, Javier, additional, Avigdor, Abraham, additional, Rule, Simon, additional, Samoilova, Olga, additional, Pavlovsky, Miguel A., additional, Goy, Andre, additional, Mato, Anthony, additional, Hallek, Michael, additional, Salman, Mariya, additional, Tamegnon, Monelle, additional, Sun, Steven, additional, Connor, Anne, additional, Nottage, Kerri, additional, Schuier, Natasha, additional, Balasubramanian, Sriram, additional, Howes, Angela, additional, and Cramer, Paula, additional

Published
2020
Full Text
View/download PDF

177. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study

Author

Donato, Michele L, primary, Park, Steven, additional, Baker, Melissa, additional, Korngold, Robert, additional, Morawski, Alison, additional, Geng, Xue, additional, Tan, Ming, additional, Ip, Andrew, additional, Goldberg, Stuart, additional, Rowley, Scott, additional, Chow, Kar, additional, Brown, Emily, additional, Zenreich, Joshua, additional, McKiernan, Phyllis, additional, Buttner, Kathryn, additional, Ullrich, Anna, additional, Long, Laura, additional, Feinman, Rena, additional, Rincourt, Andrea, additional, Kemp, Marlo, additional, Vendivil, Mariefel, additional, Suh, Hyung, additional, Balani, Bindu, additional, Cicogna, Cristina, additional, Sebti, Rani, additional, Al-Khan, Abdulla, additional, Sperber, Steven, additional, Desai, Samit, additional, Fanning, Stacey, additional, Arad, Danit, additional, Go, Ronaldo, additional, Tam, Elizabeth, additional, Rose, Keith, additional, Sadikot, Sean, additional, Siegel, David, additional, Gutierrez, Martin, additional, Feldman, Tatyana, additional, Goy, Andre, additional, Pecora, Andrew, additional, Biran, Noa, additional, Leslie, Lori, additional, Gillio, Alfred, additional, Timmapuri, Sarah, additional, Boonstra, Michele, additional, Singer, Sam, additional, Kaur, Sukhdeep, additional, Richards, Ernest, additional, and Perlin, David S, additional

Published
2020
Full Text
View/download PDF

178. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Author

Roschewski, Mark, primary, Lionakis, Michail S., additional, Sharman, Jeff P., additional, Roswarski, Joseph, additional, Goy, Andre, additional, Monticelli, M. Andrew, additional, Roshon, Michael, additional, Wrzesinski, Stephen H., additional, Desai, Jigar V., additional, Zarakas, Marissa A., additional, Collen, Jacob, additional, Rose, Keith M., additional, Hamdy, Ahmed, additional, Izumi, Raquel, additional, Wright, George W., additional, Chung, Kevin K., additional, Baselga, Jose, additional, Staudt, Louis M., additional, and Wilson, Wyndham H., additional

Published
2020
Full Text
View/download PDF

179. Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial.

Author

Wang, Michael, primary, Rossi, John M., additional, Munoz, Javier, additional, Goy, Andre, additional, Locke, Frederick Lundry, additional, Reagan, Patrick Michael, additional, Jacobson, Caron A., additional, Hill, Brian T, additional, Holmes, Houston, additional, Jaglowski, Samantha Mary, additional, Peng, Weimin, additional, Zheng, Lianqing, additional, Fang, Xiang, additional, Xue, Allen, additional, Rao, Arati V., additional, and Bot, Adrian, additional

Published
2020
Full Text
View/download PDF

180. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Author

Wang, Michael, primary, Munoz, Javier, additional, Goy, Andre, additional, Locke, Frederick L., additional, Jacobson, Caron A., additional, Hill, Brian T., additional, Timmerman, John M., additional, Holmes, Houston, additional, Jaglowski, Samantha, additional, Flinn, Ian W., additional, McSweeney, Peter A., additional, Miklos, David B., additional, Pagel, John M., additional, Kersten, Marie-Jose, additional, Milpied, Noel, additional, Fung, Henry, additional, Topp, Max S., additional, Houot, Roch, additional, Beitinjaneh, Amer, additional, Peng, Weimin, additional, Zheng, Lianqing, additional, Rossi, John M., additional, Jain, Rajul K., additional, Rao, Arati V., additional, and Reagan, Patrick M., additional

Published
2020
Full Text
View/download PDF

181. Selinexor in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (SADAL): A Single-Arm Multinational Phase 2 Trial

Author

Kalakonda, Nagesh, primary, Maerevoet, Marie, additional, Cavallo, Federica, additional, Follows, George, additional, Goy, Andre, additional, Vermaat, Joost S.P., additional, Casasnovas, Olivier, additional, Hamad, Nada, additional, Zijlstra, Josee M., additional, Bakhshi, Sameer, additional, Bouabdallah, Reda, additional, Choquet, Sylvain, additional, Gurion, Ronit, additional, Hill, Brian T., additional, Jaeger, Ulrich, additional, Sancho, Juan Manuel, additional, Schuster, Michael, additional, Thieblemont, Catherine, additional, de la Cruz, Fatima, additional, Egyed, Miklos, additional, Mishra, Sourav, additional, Offner, Fritz, additional, Vassilakopoulos, Theodoros, additional, Warzocha, Krzysztof, additional, McCarthy, Daniel, additional, Ma, Xiwen, additional, Corona, Kelly, additional, Saint-Martin, Jean-Richard, additional, Chang, Hua, additional, Landesman, Yosef, additional, Joshi, Anita, additional, Wang, Hongwei, additional, Shah, Jatin, additional, Shacham, Sharon, additional, Kauffman, Michael, additional, Van den Neste, Eric, additional, and Canales, Miguel, additional

Published
2020
Full Text
View/download PDF

183. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

Author

Romaguera, Jorge E., Fayad, Luis E., Feng, Lei, Hartig, Kimberly, Weaver, Pamela, Rodriguez, Maria Alma, Hagemeister, Fredrick B., Pro, Barbara, McLaughlin, Peter, Younes, Anas, Samaniego, Felipe, Goy, Andre, Cabanillas, Fernando, Kantarjian, Hagop, Kwak, Larry, and Wang, Michael

Published
2010
Full Text
View/download PDF

184. Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Author

Ramchandren, Radhakrishnan, primary, Johnson, Peter, primary, Ghosh, Nilanjan, primary, Ruan, Jia, primary, Ardeshna, Kirit M., primary, Johnson, Roderick, primary, Verhoef, Gregor, primary, Cunningham, David, primary, de Vos, Sven, primary, Kassam, Shireen, primary, Fayad, Luis, primary, Radford, John, primary, Bailly, Sarah, primary, Offner, Fritz, primary, Morgan, David, primary, Munoz, Javier, primary, Ping, Jerry, primary, Kwei, Kevin, primary, Eckert, Karl, primary, Neuenburg, Jutta K., primary, and Goy, Andre, primary

Published
2019
Full Text
View/download PDF

185. A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents: Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life

Author

Ujjani, Chaitra, primary, Mato, Anthony R., additional, Cohen, Jonathon B., additional, Svoboda, Jakub, additional, Andorsky, David, additional, Goy, Andre, additional, Wang, Michael L., additional, Kumar, Anita, additional, Torney, Peggy Ann, additional, Dawson, Michelle, additional, Elesinmogun, Cynthia, additional, Kabadi, Shaum M, additional, Seal, Brian, additional, Pagel, John M., additional, and Ramsey, Scott D, additional

Published
2019
Full Text
View/download PDF

186. Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation

Author

McKenna, Marshall, primary, McKiernan, Phyllis, additional, Siegel, David S., additional, Rowley, Scott D., additional, Biran, Noa, additional, Vesole, David H., additional, Goldberg, Stuart L., additional, Nyirenda, Themba, additional, Pecora, Andrew L., additional, Goy, Andre, additional, and Donato, Michele L., additional

Published
2019
Full Text
View/download PDF

187. Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

Author

Kollimuttathuliam, Sudarsan, primary, McKiernan, Phyllis, additional, Siegel, David S., additional, Rowley, Scott D., additional, Biran, Noa, additional, Vesole, David H., additional, Nyirenda, Themba, additional, Pecora, Andrew L., additional, Goldberg, Stuart L., additional, Goy, Andre, additional, and Donato, Michele L., additional

Published
2019
Full Text
View/download PDF

188. Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Author

Jain, Michael D., primary, Jacobs, Miriam T., primary, Nastoupil, Loretta J., primary, Spiegel, Jay Y., primary, Feng, Gao, primary, Lin, Yi, primary, Lunning, Matthew A., primary, Dahiya, Saurabh, primary, Lekakis, Lazaros J, primary, Reagan, Patrick M, primary, Oluwole, Olalekan O., primary, McGuirk, Joseph P., primary, Deol, Abhinav, primary, Goy, Andre, primary, Hill, Brian T., primary, Munoz, Javier, primary, Chavez, Julio, primary, Rapoport, Aaron P., primary, Vose, Julie M, primary, Miklos, David B, primary, Neelapu, Sattva S, primary, Bennani, N. Nora, primary, Andreadis, Charalambos, primary, Sehgal, Alison R., primary, Ghobadi, Armin, primary, and Locke, Frederick L., primary

Published
2019
Full Text
View/download PDF

189. Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Author

Jacobs, Miriam T., primary, Jain, Michael D., additional, Spiegel, Jay Y., additional, Nastoupil, Loretta J., additional, Li, Yibo, additional, Feng, Gao, additional, Lunning, Matthew A., additional, Lekakis, Lazaros J, additional, Dahiya, Saurabh, additional, Reagan, Patrick M, additional, Oluwole, Olalekan O., additional, McGuirk, Joseph P., additional, Deol, Abhinav, additional, Sehgal, Alison R., additional, Goy, Andre, additional, Hill, Brian T., additional, Andreadis, Charalambos, additional, Munoz, Javier, additional, Chavez, Julio, additional, Bennani, N. Nora, additional, Rapoport, Aaron P., additional, Vose, Julie M, additional, Miklos, David B, additional, Neelapu, Sattva S, additional, Ghobadi, Armin, additional, and Locke, Frederick L., additional

Published
2019
Full Text
View/download PDF

190. Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

Author

Bennani, N. Nora, primary, Maurer, Matthew J., primary, Nastoupil, Loretta J., primary, Jain, Michael D., primary, Chavez, Julio C., primary, Cashen, Amanda F, primary, Dahiya, Saurabh, primary, Lekakis, Lazaros J., primary, Reagan, Patrick M, primary, Oluwole, Olalekan O., primary, McGuirk, Joseph P., primary, Deol, Abhinav, primary, Sehgal, Alison R., primary, Goy, Andre, primary, Hill, Brian T., primary, Vu, Khoan, primary, Andreadis, Charalambos, primary, Munoz, Javier, primary, Rapoport, Aaron P., primary, Vose, Julie M, primary, Miklos, David B, primary, Locke, Frederick L., primary, Neelapu, Sattva S, primary, and Lin, Yi, primary

Published
2019
Full Text
View/download PDF

191. Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients

Author

Yazdy, Maryam Sarraf, primary, Mato, Anthony R., additional, Roeker, Lindsey E., additional, Jarral, Umair, additional, Ujjani, Chaitra S., additional, Shadman, Mazyar, additional, Skarbnik, Alan, additional, Whitaker, Kate J, additional, Deonarine, Isaac, additional, Kabel, Charlene C., additional, Stump, Sarah E., additional, Goodfriend, Julie, additional, Pagel, John M., additional, Bailey, Neil, additional, Patel, Krish, additional, Jacobs, Ryan, additional, Feldman, Tatyana A., additional, Leslie, Lori A., additional, Goy, Andre, additional, Coombs, Catherine C., additional, Muluneh, Benyam, additional, Khajavian, Sirin, additional, Lamanna, Nicole, additional, Weissbrot, Hanna, additional, Weiss, Jessica, additional, and Cheson, Bruce D., additional

Published
2019
Full Text
View/download PDF

192. Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up

Author

Rule, Simon, primary, Dreyling, Martin H., additional, Goy, Andre, additional, Hess, Georg, additional, Auer, Rebecca, additional, Kahl, Brad S., additional, Hernandez-Rivas, Jose Angel, additional, Qi, Keqin, additional, Deshpande, Sanjay, additional, Parisi, Lori, additional, and Wang, Michael L., additional

Published
2019
Full Text
View/download PDF

193. Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study

Author

Cavallo, Federica, primary, Follows, George A, additional, Goy, Andre, additional, Vermaat, Joost, additional, Casasnovas, Rene-Olivier, additional, Lavee, Orly, additional, Maerevoet, Marie, additional, Zijlstra, Josée M, additional, Bakhshi, Sameer, additional, Bouabdallah, Reda, additional, Choquet, Sylvain, additional, Gurion, Ronit, additional, Hill, Brian T., additional, Jaeger, Ulrich, additional, Sancho, Juan-Manuel, additional, Schuster, Michael W., additional, Thieblemont, Catherine, additional, De la Cruz, Fatima, additional, Egyed, Miklos, additional, Mishra, Sourav, additional, Offner, Fritz, additional, Vassilakopoulos, Theodoros P., additional, Warzocha, Krzysztof, additional, McCarthy, Daniel, additional, Ma, Xiwen, additional, Corona, Kelly, additional, Saint-Martin, Jean-Richard, additional, Joshi, Anita, additional, Shah, Jatin, additional, Van Den Neste, Eric, additional, Canales, Miguel A, additional, and Kalakonda, Nagesh, additional

Published
2019
Full Text
View/download PDF

194. KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study

Author

Wang, Michael L., primary, Munoz, Javier, primary, Goy, Andre, primary, Locke, Frederick L., primary, Jacobson, Caron A., primary, Hill, Brian T., primary, Timmerman, John M., primary, Holmes, Houston, primary, Jaglowski, Samantha, primary, Flinn, Ian W., primary, McSweeney, Peter A., primary, Miklos, David B., primary, Pagel, John M., primary, Kersten, Marie Jose, primary, Peng, Weimin, primary, Zheng, Lianqing, primary, Rossi, John M., primary, Jain, Rajul K., primary, Rao, Arati V., primary, and Reagan, Patrick M, primary

Published
2019
Full Text
View/download PDF

196. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma

Author

Herrera, Alex F., primary, Goy, Andre, additional, Mehta, Amitkumar, additional, Ramchandren, Radhakrishnan, additional, Pagel, John M., additional, Svoboda, Jakub, additional, Guan, Shanhong, additional, Hill, John S., additional, Kwei, Kevin, additional, Liu, Emily A., additional, and Phillips, Tycel, additional

Published
2019
Full Text
View/download PDF

197. Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPs

Author

Do, Catherine, primary, Dumont, Emmanuel LP, additional, Salas, Martha, additional, Castano, Angelica, additional, Mujahed, Huthayfa, additional, Maldonado, Leonel, additional, Singh, Arunjot, additional, DaSilva-Arnold, Sonia C., additional, Bhagat, Govind, additional, Lehman, Soren, additional, Christiano, Angela M., additional, Madhavan, Subha, additional, Nagy, Peter L., additional, Green, Peter H.R., additional, Feinman, Rena, additional, Trimble, Cornelia, additional, Illsley, Nicholas P., additional, Marder, Karen, additional, Honig, Lawrence, additional, Monk, Catherine, additional, Goy, Andre, additional, Chow, Kar, additional, Goldlust, Samuel, additional, Kaptain, George, additional, Siegel, David, additional, and Tycko, Benjamin, additional

Published
2019
Full Text
View/download PDF

200. A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Author

Kalakonda, Nagesh Cavallo, Federica Follows, George Goy, Andre Vermaat, Joost S. P. Casasnovas, Olivier Lavee, Orly and Maerevoet, Marie Zijlstra, Josee Bakhshi, Sameer and Bouabdallah, Reda Choquet, Sylvain Gurion, Ronit Hill, Brian and Jaeger, Ulrich Sancho, Juan-Manuel Schuster, Michael and Thieblemont, Catherine De la Cruz, Fatima Egyed, Miklos and Mishra, Sourav Offner, Fritz Vassilakopoulos, Theodoros and Warzocha, Krzysztof McCarthy, Daniel Ma, Xiwen Corona, Kelly and Saint-Martin, Jean-Richard Joshi, Anita Shah, Jatin Van den Neste, Eric Canales, Miguel

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results